Tyrosine kinase inhibitors

A compound of Formula I

• or a pharmaceutically acceptable salt or stereoisomer thereof, wherein
• Y is S;
• Q is O or absent;
• R1 is:
• 1) Or(C1-C6)perfluoroalkyl,
• 2) OH,
• 3) CN,
• 4) halogen,
• 5) (C═O)rOs(C1-C10)alkyl,
• 6) (C═O)rOs(C2-C8)cycloalkyl,
• 7) (C═O)rOs(C2-C10)alkenyl,
• 8) (C═O)rOs(C2-C10)alkynyl,
• 9) (C═O)rOsaryl,
• 10) (C═O)rOsheterocyclyl, or
• 11) NRaRb,
• wherein r and s are independently 0 or 1, and said alkyl, cycloalkyl, alkenyl, alkynyl, aryl, and heterocyclyl is optionally substituted with one or more substituents selected from R7;
• R2 is R1 or H;
• R4 is H or (C1-C6)alkyl;
• R5 is:
• 1) H,
• 2) SO2Rc,
• 3) (C═O)rRc, wherein r is 0 or 1, or
• 4) CO2Rc;
• R7 is:
• 1) Or(C═O)sNRaRb,
• 2) (C═O)rOsaryl,
• 3) (C═O)rOs-heterocyclyl,
• 4) halogen,
• 5) OH,
• 6) oxo,
• 7) O(C1-C3)perfluoroalkyl,
• 8) (C1-C3)perfluoroalkyl,
• 9) (C═O)rOs(C1-C10)alkyl,
• 10) CHO,
• 11) C2H,
• 12) CN, or
• 13) (C3-C8)cycloalkyl,
• wherein r and s are independently 0 or 1, and said aryl, heterocyclyl and cycloalkyl are optionally substituted with one or more substituents selected from Rd;
• Ra and Rb are independently:
• 1) H,
• 2) (C═O)r( C1-C10)alkyl,
• 3) (C═O)r(C3-C6)cycloalkyl,
• 4) S(O)2Rc,
• 5) (C═O)rheterocyclyl,
• 6) (C═O)raryl, or
• 7) CO2Rc,
• wherein r is 0 or 1 and said alkyl, cycloalkyl, heterocyclyl, and aryl optionally substituted with one or more substituents selected from Rd, or
• Ra and Rb are taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from Rd;
• Rc is (C1-C6)alkyl, (C3-C6)cycloalkyl, aryl, or heterocyclyl;
• Rd is selected from:
• 1) (C═O)rOs(C1-C10)alkyl, wherein r and s are independently 0 or 1, optionally substituted with up to three substituents selected from OH, (C1-C6)alkoxy, halogen, CN, oxo, N(Re)2 and S(O)2Rc,
• 2) Or(C1-C3)perfluoroalkyl,
• 3) (C0-C6)alkylene-S(O)mRc, wherein m is 0, 1, or 2,
• 4) oxo,
• 5) OH,
• 6) halo,
• 7) CN,
• 8) (C3-C6)cycloalkyl, optionally substituted with up to three substituents selected from OH, (C1-C6)alkoxy, halogen, CN, oxo, N(Re)2, and S(O)2Rc,
• 9) (C0-C6)alkylene-aryl), optionally substituted with up to three substituents selected from Re,
• 10) (C0-C6)alkylene-heterocyclyl, optionally substituted with up to three substituents selected from Re,
• 11) (C0-C6)alkylene-N(Re)2,
• 12) C(O)Rc,
• 13) CO2Rc,
• 14) C(O)H, and
• 15) CO2H;
• and
• Re is H, (C1-C6)alkyl, aryl, heterocyclyl, (C3-C6)cycloalkyl or S(O)2Rc;
• and as used herein, the term “heterocycle” or “heterocyclyl” is a 5- to 10-membered aromatic or nonaromatic, monocyclic or bicyclic, heterocycle, containing from 1 to 4 heteroatoms selected from the group consisting of O, N and S.